The clinical utility of Memorial Symptom Assessment‐Short Form and Condensed Memorial Symptom Assessment Scale in Turkish lung cancer patients

Abstract

Introduction: Symptom assessment is essential in the palliative care of patients with cancer. We studied the Memorial Assessment Scale Test-Short Form (MSAS-SF) and Condensed Memorial Assessment Test (CMSAS) in Turkish lung cancer patients. Material and Method: Fifty-one patients with lung cancer (47 non-small, 4 small cell) were staged according to the International Association for the Study of Lung Cancer 2007 and filled the MSAS-SF. Karnofsky performance status, TNM staging, MSAS-SF and CMSAS scores were recorded. The study was approved by the local research ethics committee. Results: The mean age of 51 patients was 61.7 ± 9. Fifty-one percent were staged as M1 while 49% were staged as M0. The mean values for global distress index, PHYS (physical symptom distress), PSYCH (psychological symptom score) and MSAS-SUM were 1.15 ± 0.8, 0.9 ± 0.8, 1.13 ± 1.03 and 0.82 ± 0.47 in order. The mean values for CPHYS (physical symptom distress for Condensed MSAS), CPSYCH (psychological symptom score for CMSAS) and CSUM (sum scores) were 1.2 ± 0.75, 1.22 ± 1.1 and 1.16 ± 0.69 in order. Cronbach's alpha coefficients for MSAS-SF and CMSAS were 0.861 and 0.728 in order. Summary scores for both MSAS-SF and CMSAS-SF were significantly higher in patients with M1 disease than from M0 disease. In addition, PHYS and MSAS-SUM in MSAS-SF were significantly correlated with T and N stage. The area under curve for MSAS-SF and CMSAS were 0.793 and 0.70 in order. Conclusion: MSAS-SF and CMSAS demonstrated significantly higher scores in lung cancer patients with M1 disease than patients with M0 disease. Further studies are needed to evaluate the usefulness of MSAS-SF and CMSAS in lung cancer patients.

Reliability and Validity of the Korean Memorial Symptom Assessment Scale—Short Form in Gynecological Cancer Patients

“…These results are similar to the finding that MSAS-SF subscale scores are significantly correlated with advanced cancer stage patients with lung cancer according to tumor, node, and metastasis (TNM) stage. 16 Despite differences in the measurement of cancer stage (TNM vs. FIGO stage), MSAS-SF score was appropriate to cancer stage differences. Moreover, MSAS-SF scores differed by KPS group in our study.…”

“…15 The MSAS-SF assesses 32 symptoms with distress for physical symptoms and frequency of psychological symptoms, with subscales for global distress, physical symptom distress, psychological symptom distress, and total MSAS (TMSAS) score. The reliability and validity of MSAS-SF has been shown in the U.S., 15 Turkey, 16 China, 17 and U.K. 18 and for patients with various cancer types, including lung, 16 colorectal, 17 advanced soft tissue sarcoma, 19 and germ cell tumors. 20 The validity of MSAS-SF has been previously demonstrated in English, 15 Chinese, 17 and Spanish.…”

Homestead together: Pediatric palliative care telehealth support for rural children with cancer during home‐based end‐of‐life care

“…The MSAS instrument was developed for oncology patients to gauge patient‐reported symptom profiles inclusive of each symptom's severity, frequency, and associated distress 22 . The validity, reliability, and responsiveness of the MSAS has been repeatedly demonstrated for evaluating symptom patterns experienced by cancer patients, including end‐of‐life symptomotology 23–28 . The original MSAS was notably developed for adult cohorts, requiring revisions for versatile and developmentally appropriate symptom assessments in pediatric patients with cancer 29,30 .…”

Progress in palliative care for cancer in Turkey: a review of the literature

“…The UABSON has collaborated with Turkish nurses and researchers to develop a PC network and research. Yüceege et al [ 105 ] English Journal paper Tool validation To identify the clinical utility of Memorial Symptom Assessment-Short Form and Condensed Memorial Symptom Assessment Scale in Turkish lung cancer patients. Memorial Symptom Assessment-Short Form and Condensed Memorial Symptom Assessment Scale can be used in lung cancer patients The Cronbach’s alpha coefficients were 0.861 (1.785–0.915) for MSAS-SF and 0.728 (0.566–0.835) for CMSAS.…”